Anne Grundschober-Freimoser

Schlieren, ZH, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

P329G-engager: a universal mix & match antibody-based adaptor platform for cancer immunotherapy.

P329G-engager: a universal mix & match antibody-based adaptor platform for cancer immunotherapy.

Journal: mAbs

Published: December 16, 2025

Optimizing efficacy and safety of T cell bispecific antibodies: the interdependence of CD3 and tumor antigen binder affinities in FOLR1 and CEACAM5 2 + 1 TCBs.

Optimizing efficacy and safety of T cell bispecific antibodies: the interdependence of CD3 and tumor antigen binder affinities in FOLR1 and CEACAM5 2 + 1 TCBs.

Journal: mAbs

Published: November 06, 2025

An alternative nonclinical approach to support the first-in-human clinical trial of a T-cell bispecific targeting EGFRvIII.

An alternative nonclinical approach to support the first-in-human clinical trial of a T-cell bispecific targeting EGFRvIII.

Journal: Journal of pharmaceutical sciences

Published: July 09, 2025

Characterization of anti-drug antibody responses to the T-cell engaging bispecific antibody cibisatamab to understand the impact on exposure.

Characterization of anti-drug antibody responses to the T-cell engaging bispecific antibody cibisatamab to understand the impact on exposure.

Journal: Frontiers in immunology

Published: March 24, 2024

Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors.

Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors.

Journal: Journal for immunotherapy of cancer

Published: June 26, 2022

A Novel EGFRvIII T-Cell Bispecific Antibody for the Treatment of Glioblastoma.

A Novel EGFRvIII T-Cell Bispecific Antibody for the Treatment of Glioblastoma.

Journal: Molecular cancer therapeutics

Published: March 25, 2022

JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy.

JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy.

Journal: Journal for immunotherapy of cancer

Published: December 11, 2021

Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy.

Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy.

Journal: mAbs

Published: May 11, 2021

PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells.

PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells.

Journal: Nature

Published: March 14, 2021

Human immunocompetent Organ-on-Chip platforms allow safety profiling of tumor-targeted T-cell bispecific antibodies.

Human immunocompetent Organ-on-Chip platforms allow safety profiling of tumor-targeted T-cell bispecific antibodies.

Journal: eLife

Published: January 31, 2021

Fibroblast Activation Protein α-Targeted CD40 Agonism Abrogates Systemic Toxicity and Enables Administration of High Doses to Induce Effective Antitumor Immunity.

Fibroblast Activation Protein α-Targeted CD40 Agonism Abrogates Systemic Toxicity and Enables Administration of High Doses to Induce Effective Antitumor Immunity.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: December 11, 2020

P329G-CAR-J: a novel Jurkat-NFAT-based CAR-T reporter system recognizing the P329G Fc mutation.

P329G-CAR-J: a novel Jurkat-NFAT-based CAR-T reporter system recognizing the P329G Fc mutation.

Journal: Protein engineering, design & selection : PEDS

Published: July 02, 2019

Showing 1-12 of 24

Last Updated: 09/26/2026